Christoph B Olivier’s Team Explores Platelet Reactivity and Fibrin Clot-Strength in AF
Jan Hartmann, Chief Medical Officer at Haemonetics, reposted from Haemonetics on LinkedIn:
”Encouraging progress in personalized cardiovascular care.
A recent paper from Christoph B Olivier’s team at my alma mater, The University of Freiburg, explores “Platelet Reactivity and Fibrin Clot-Strength as assessed by TEG in Patients with Atrial Fibrillation undergoing Percutaneous Coronary Intervention”.
Their findings suggest that combined high platelet reactivity and increased platelet–fibrin clot strength after the PCI may elevate ischemic risk—though neither factor alone was predictive.
This aligns with data in broader post-PCI populations, with or without AFib:
- Young-Hoon Jeong, MD, PhD’s team (European Heart Journal, 2024) in South Korea showed that patients with combined platelet-fibrin clot strength and high platelet reactivity had the highest risk for MACE post-PCI (more than patients with either factor alone).
- A 2023 study from Fudan University in China reported similar results, where “a combination of high fibrinogen and HRPR may identify recurrent adverse ischemic events over 12 months.”
It’s encouraging to see continued momentum toward individualized post-intervention strategies, especially in tailoring OAC and antiplatelet therapy.
References:
Read the full article here.
Article: Platelet Reactivity and Fibrin Clot-Strength as assessed by TEG in Patients with Atrial Fibrillation undergoing Percutaneous Coronary Intervention
Authors: Diona Gjermeni, Hannah Vetter, Sofia Szabó, Viktoria Anfang, Carina Juelch, Stefan Leggewie, David Hesselbarth, Markus Jäckel, Daniel Duerschmied, Dietmar Trenk, Dirk Westermann, Christoph B Olivier
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Apr 4, 2026, 09:21Moustafa Abdou: New Horizons in Hematology and Recent Drug Approvals
-
Apr 4, 2026, 09:13David McIntosh: From Western Dominance to LMIC Influence in Plasma Medicine with SK Plasma
-
Apr 4, 2026, 09:03Thomas Pincez: Mechanisms and Pathology of Immune Thrombocytopenia
-
Apr 4, 2026, 08:36Sylvain Perruche: Reactivating the Body Own Resolution Program in Inflammatory Disease
-
Apr 4, 2026, 08:27Daniel Pereira Monteiro: HbF Raised with HbC and HbA – What to Do Next?
-
Apr 4, 2026, 08:13Eoin McGrath: Common Language for Blood Transfer Across Organizations
-
Apr 3, 2026, 17:59A Free Hemoglobin Screening Camp for Kaikadi Vasti and Eramushti Community Women – Hope Foundation Sironcha
-
Apr 3, 2026, 17:53Carlos Henrique Del Carlo: HFpEF and Iron Deficiency – Why Treating the Mitochondrial Engine Matters More Than We Thought?
-
Apr 3, 2026, 17:46Michelle Leona Cecil: A Call to Protect Patient Care and The Nation’s Blood Supply for Blood Disorders Community